Erdrp-0519
ERDRP-0519 is an antiviral drug which is the first drug specifically developed to target the measles morbillivirus.
It acts as an inhibitor of the viral enzyme RNA polymerase which is essential for viral replication, and in animal studies showed good oral bioavailability and protected ferrets from otherwise lethal doses of a morbillivirus when administered up to three days after infection.
 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C23H30F3N5O4S |
| Molar mass | 529.58 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
History
The research was done at Georgia State University and the Paul Ehrlich Institute.
See also
References
This article uses material from the Wikipedia English article ERDRP-0519, which is released under the Creative Commons Attribution-ShareAlike 3.0 license ("CC BY-SA 3.0"); additional terms may apply (view authors). Content is available under CC BY-SA 4.0 unless otherwise noted. Images, videos and audio are available under their respective licenses.
®Wikipedia is a registered trademark of the Wiki Foundation, Inc. Wiki English (DUHOCTRUNGQUOC.VN) is an independent company and has no affiliation with Wiki Foundation.